Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 44

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Dementia+1

Recruiting

Study on the Use of Flortaucipir for Diagnosing Mild Cognitive Impairment and Dementia in Patients

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Flortaucipir (18F)
  • Sponsor:Amsterdam UMC Stichting

Study on the Safety and Effects of Radiprodil for Children with GRIN-related Disorder

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Radiprodil
  • Sponsor:Grin Therapeutics Inc.

Trisomy 21+1

Recruiting

Study on Sleep and Temperature Changes in Alzheimer’s Disease for Down Syndrome Patients Using Izaflortaucipir (18F)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Izaflortaucipir (18F)
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Study on the Effects of Avalglucosidase Alfa Enzyme Replacement Therapy in Patients with Pompe Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Region Hovedstaden

Study on Gene Therapy with AAV9.LAMP2B for Male Patients with Danon Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Rocket Pharmaceuticals Inc.

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Turku University Hospital

Study on the Safety and Effects of ACI-24.060 for Patients with Early Alzheimer's Disease and Adults with Down Syndrome

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:AC Immune S.A.

Study on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Alpelisib
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Study on the Safety and Effects of ACI-7104.056 in Patients with Early Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:AC Immune S.A.

Study on the Safety and Effectiveness of Semaglutide for Non-Diabetic Patients with Acute Ischemic Stroke

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Region Midtjylland

Study of Incobotulinumtoxin-A Injections for Diabetic Neuropathic Pain in the Lower Limbs

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.